Objective: To evaluate the clinical efficacy and safety of Shugan Jianpi Recipe in the treatment of subclinical hypothyroidism with liver stagnation and spleen deficiency.Methods:From December 2017 to February 2019,sixty-three patients with subclinical hypothyroidism with liver stagnation and spleen deficiency who met the inclusion criteria in the outpatient department and inpatients of Urumqi Hospital of Traditional Chinese Medicine were randomly divided into the experimental group and the control group.The group(30 cases)was given orally to Shugan Jianpi Recipe,and the control group(33 cases)was given placebo orally.Both groups were given medication for1 month and followed up for 3 months.Observed and recorded three groups before and after treatment of thyroid function(TSH,FT4,FT3)as well as changes in plasma lipid(TG,TC,HDL-C,LDL-C)and symptom score of TCM,using SPSS 24.0 software for statistical analysis.Results: A total of 63 patients were enrolled in the study.Of the 5patients who were absent during the study,58 patients completed the trial and the shedding rate was 7.9%.Before and after treatment,the two groups of patients were compared with those before treatment.(1)The levels of TSH and LDL-C in the experimental group were lower than before,and the differences of FT4,FT3,TC,TG and HDL-C were not statistically significant(P>0.05);TSH,FT4,FT3,TG in the control group.There were no significant differences in the changes of TC,LDL-C and HDL-C(P>0.05).(2)Before and after treatment of TCM symptom scores in the two groups,the total scores of TCM symptoms in the experimental group and the control group were improved,the difference was statistically significant(P<0.05);the improvement of the test group was compared by the difference of the integrals.Compared with the control group,the difference was statistically significant(P<0.05).(3)The efficacy of the two groups was71%,and the total effective rate was 30%.The difference was statistically significant(P<0.05).Conclusion: Shugan Jianpi Recipe can effectively reduce thyrotropin andlow-density lipoprotein levels in the treatment of liver-stagnation and spleen-deficiency subclinical hypothyroidism with good safety. |